brain surgery at Stanford University. The segment (episode 5) is
scheduled to be rebroadcast tonight, May 9, at 8:30 p.m. and 11:30 p.m.
For the quarter ended March 31, 2008, the Company reported a net loss of $6.7 million, or $0.16 per share, which included research and development costs totaling $3.4 million and selling, general and administrative expenses of $3.4 million. Non-cash charges relating to stock-based compensation, depreciation and amortization for the first quarter of fiscal 2008 totaled $906,000. Total revenue for the first quarter 2008 was $646,000, compared to $309,000 for the same quarter last year. The increase in revenue was a result of an increase in InnerCool sales resulting from our expanded sales and marketing efforts. Cash and cash equivalents as of March 31, 2008 were $6.3 million.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies,
Inc. and the Tissue Repair Company, are medical technology companies
primarily focused on the development, manufacture and sale of innovative
therapeutic products and devices for cardiovascular, ischemic and related
indications. Cardium's lead product candidate, Generx (alferminogene
tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being
developed for potential use by interventional cardiologists as a one-time
treatment to promote and stimulate the growth of collateral circulation in
the hearts of patients with ischemic conditions such as recurrent angina.
For more information about Cardium Therapeutics and its businesses,
products and therapeutic candidates, please visit http://www.cardiumthx.com
or view its 2007 Annual Report at
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved